Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 392 (10149), 787-790

Prevention of Ebola Virus Disease Through Vaccination: Where We Are in 2018

Affiliations

Prevention of Ebola Virus Disease Through Vaccination: Where We Are in 2018

Yves Lévy et al. Lancet.

Conflict of interest statement

Declaration of interests

CLan reports receipt of products for evaluation in clinical trials from various pharmaceutical companies, including Merck, GlaxoSmithKline, Johnson & Johnson, and Gilead; the clinical trials in which these products are used are not funded by the pharmaceutical companies. PP reports grants from the European Innovative Medicines Initiative outside of the submitted work. DW-J is an investigator on several clinical trials of prophylactic Ebola vaccines. HL reports grants from GlaxoSmithKline and other support from Merck in relation to the submitted work. RT reports grants from the European Innovative Medicines Initiative (Janssen) in relation to the submitted work. AA reports grants from the Alliance for International Medical Action in relation to the submitted work. DI reports non-financial support from Janssen and Merck in relation to the submitted work. GC reports grants from Inserm, and other support from Janssen and Merck in relation to the submitted work. BG reports grants from the Innovative Medicines Initiative (to the London School of Hygiene & Tropical Medicine) in relation to the submitted work. JN reports grants from National Institutes of Health in relation to the submitted work. YY reports receipt of consultancy honoraria from AbbVie, Bristol-Myers Squibb, Gilead, MSD, Pfizer, Johnson & Johnson, and ViiV Healthcare outside the topic of this work, prior to November, 2016. All other authors declare no competing interests.

Similar articles

See all similar articles

Cited by 10 PubMed Central articles

See all "Cited by" articles

MeSH terms

Feedback